Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03274076 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Phase 1 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03274076 is a Phase 1 study that has completed, run by University of Michigan. The registered enrollment target is 15 participants.
The verdict
NCT03274076, a Phase 1 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This Phase I/II placebo controlled trial will evaluate tofacitinib in subjects with diffuse cutaneous systemic scleroderma (dcSSc). This trial is intended to provide safety, and tolerability data in participants with dcSSc when dosed to target exposures similar to that used in adult participants with rheumatoid arthritis.
Interventions
- DRUG Tofacitinib
- DRUG Placebo Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-09-25 |
| Est. Completion | 2019-11-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03274076
The ClinicalTrials.gov registry entry for NCT03274076 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tofacitinib is the first listed.
NCT03274076 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03274076 about?
NCT03274076 is a clinical study titled "Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)". This Phase I/II placebo controlled trial will evaluate tofacitinib in subjects with diffuse cutaneous systemic scleroderma (dcSSc). This trial is intended to provide safety, and tolerability data in participants with dcSSc when dosed to target exposures similar to that used in adult participants wit...
What is the current status of trial NCT03274076?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2017-09-25. Estimated completion is 2019-11-15.
What interventions are being tested in trial NCT03274076?
The interventions under investigation include: Tofacitinib (DRUG), Placebo Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT03274076?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.